Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims’ Data

BACKGROUND/AIMS: The introduction of direct-acting antivirals (DAA) in 2013 revolutionized hepatitis C virus (HCV) treatment, offering a cure rate >90%. However, this therapy is expensive, and estimations of the number of chronic HCV-infected (CHC) patients and their treatment costs pre-2013 are...

Descripción completa

Detalles Bibliográficos
Autores principales: Ki, Moran, Choi, Hwa Young, Kim, Kyung-Ah, Jang, Eun Sun, Jeong, Sook-Hyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669600/
https://www.ncbi.nlm.nih.gov/pubmed/28798283
http://dx.doi.org/10.5009/gnl17034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5669600/
https://www.ncbi.nlm.nih.gov/pubmed/28798283
http://dx.doi.org/10.5009/gnl17034

Ejemplares similares